Joseph Cesanek, MD
Family Medicine · Wind Gap, PANPI 1053327106
Payments from drug & device makers
Across 363 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$942
- Lilly USA, LLC$818
- Boehringer Ingelheim$499
- Sanofi-aventis U.S. LLC$478
- Astellas Pharma US Inc$389
- plus $3K from 31 others
What the payments were for
- Consulting fees$300%
- Speaking & faculty fees$5608%
- Food & beverage$6,16989%
- Education$2103%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 57 | $1,057 |
| Novo Nordisk | 60 | $942 |
| Lilly USA, LLC | 52 | $818 |
| Boehringer Ingelheim | 24 | $499 |
| Sanofi-aventis U.S. LLC | 12 | $478 |
| Astellas Pharma US Inc | 13 | $389 |
| Pfizer | 22 | $378 |
| AbbVie | 15 | $346 |
| Sanofi | 2 | $240 |
| Amgen | 12 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $176 |
| Exact Sciences | 10 | $171 |
| Abbott | 7 | $140 |
| GSK | 7 | $137 |
| Esperion Therapeutics, Inc. | 5 | $104 |
| Philips North America LLC | 4 | $103 |
| Merck | 6 | $102 |
| Phathom Pharmaceuticals, Inc. | 6 | $97 |
| Novartis | 5 | $93 |
| Amarin Pharma, Inc. | 4 | $69 |
| Almatica Pharma LLC | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Braemar Manufacturing, LLC | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $19 |
| Tonix Medicines, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$480
How this compares
$6,969 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 528 | $312,539 |
| JardianceEmpagliflozin | 144 | $134,149 |
| TrulicityDulaglutide | 90 | $114,195 |
| XareltoRivaroxaban | 102 | $85,183 |
| MounjaroTirzepatide | 50 | $58,102 |
| JanuviaSitagliptin Phosphate | 51 | $48,745 |
| OzempicSemaglutide | 34 | $44,826 |
| Bydureon BciseExenatide Microspheres | 12 | $29,398 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,078 |
| OxycontinOxycodone Hcl | 23 | $22,800 |
| WegovySemaglutide | 14 | $20,966 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $20,884 |
| TradjentaLinagliptin | 21 | $19,737 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $19,719 |
| LinzessLinaclotide | 31 | $19,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica | $378 | $319,968539 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Combivent Respimat | $499 | $173,287201 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $818 | $172,297140 claims |
| Novo NordiskOzempic, Wegovy | $942 | $65,79248 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $137 | $56,872114 claims |
| MerckJanuvia | $102 | $48,74551 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,057 | $40,14761 claims |
| AbbVieLinzess, Creon, Fetzima | $346 | $39,53760 claims |
| Astellas Pharma US IncMyrbetriq | $389 | $18,46327 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $176 | $18,17024 claims |
| NovartisEntresto | $93 | $7,60611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Wind Gap
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.